JAMA Research Letter Links Semaglutide To Gastroparesis Risk A 2023 research letter in JAMA found that users of weight loss medications semaglutide and liraglutide, the active ingredient in Victoza and Saxenda, experienced gastroparesis nearly three times as often as those on bupropion-naltrexone (Contrave), another weight-loss drug
[DOI] [PMC free article] [PubMed] [Google Scholar] 171.Mac Nair C.E., Nickells R.W
Medicare CareFirst members should ask about the GLP-1 Bridge (launching July 1, 2026, $50/month outside Part D)
Medical Supervision: Always use Ozempic under the guidance of a healthcare provider, as its important to tailor the dosage to your specific needs and monitor your progress
Here are essential insights to help you make informed decisions: GLP-1 medications like semaglutide are clinically backed tools in weight management, most effective as part of a provider-guided plan
During that first 36 weeks, the weight and heart health of the participants improved